Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02576275 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | withdrawn | Phase 3 | 0 | SecuraBioINDUSTRY | 1 | Mar 17, 2021 |
| clinicaltrials |
| NCT02085655 | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | unknown | Phase 3 | 264 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03440411 | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment(PO-3887) | terminated | Phase 3 | 9 | Fondazione EMN Italy OnlusOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | completed | Phase 3 | 181 | Pharmacyclics LLC.INDUSTRY | 9 | Mar 3, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)(ALCANZA) | completed | Phase 3 | 131 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Jan 5, 2021 | clinicaltrials |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)(Javelin DLBCL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT01102426 | Aplidin - Dexamethasone in Relapsed/Refractory Myeloma(ADMYRE) | completed | Phase 3 | 255 | PharmaMarINDUSTRY | 19 | Nov 10, 2020 | clinicaltrials |
| NCT02809053 | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma(RAMO-2) | completed | Phase 3 | 315 | Archigen Biotech LimitedINDUSTRY | 14 | Oct 8, 2020 | clinicaltrials |
| NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03242902 | To Decrease Fatigue With Light Therapy(SPARKLE) | completed | Phase 3 | 166 | The Netherlands Cancer InstituteOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT00491491 | Zevalin-beam for Aggressive Lymphoma | completed | Phase 3 | 60 | Sheba Medical CenterOTHER_GOV | 4 | Aug 31, 2020 | clinicaltrials |
| NCT02867566 | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | completed | Phase 3 | 420 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01285765 | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 14, 2020 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02322320 | Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | completed | Phase 3 | 273 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 11, 2020 | clinicaltrials |
| NCT01413178 | A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 3 | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT01829711 | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | completed | Phase 3 | 80 | MedImmune LLCINDUSTRY | 14 | Apr 8, 2020 | clinicaltrials |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy(A+B) | terminated | Phase 3 | 346 | Novartis PharmaceuticalsINDUSTRY | 17 | Mar 27, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT02162771 | To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan(rituximab) | completed | Phase 3 | 140 | CelltrionINDUSTRY | 0 | Jan 29, 2020 | clinicaltrials |
| NCT01059630 | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | completed | Phase 3 | 413 | Genentech, Inc.INDUSTRY | 14 | Jan 13, 2020 | clinicaltrials |
| NCT03670901 | A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 3 | 8 | JHL Biotech, Inc.INDUSTRY | 1 | Jan 9, 2020 | clinicaltrials |
| NCT01146834 | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | completed | Phase 3 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(RESONATE™) | completed | Phase 3 | 391 | Pharmacyclics LLC.INDUSTRY | 10 | Dec 18, 2019 | clinicaltrials |
| NCT01197560 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 / Phase 3 | 111 | CelgeneINDUSTRY | 9 | Nov 25, 2019 | clinicaltrials |
| NCT00622336 | A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | completed | Phase 3 | 330 | CelgeneINDUSTRY | 2 | Nov 20, 2019 | clinicaltrials |
| NCT00689936 | Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma(FIRST) | completed | Phase 3 | 1,623 | CelgeneINDUSTRY | 19 | Nov 20, 2019 | clinicaltrials |
| NCT00928486 | A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 25 | CelgeneINDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT01021423 | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).(RENEW) | terminated | Phase 3 | 9 | CelgeneINDUSTRY | 12 | Nov 19, 2019 | clinicaltrials |
| NCT01324947 | Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | completed | Phase 3 | 74 | CelgeneINDUSTRY | 15 | Nov 19, 2019 | clinicaltrials |
| NCT00452569 | Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma(OPTIMUM) | completed | Phase 3 | 499 | CelgeneINDUSTRY | 15 | Nov 18, 2019 | clinicaltrials |
| NCT02811978 | Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 3 | 81 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00657488 | Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 400 | CelgeneINDUSTRY | 2 | Oct 18, 2019 | clinicaltrials |
| NCT03349333 | A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL | completed | Phase 3 | 85 | Mundipharma (China) Pharmaceutical Co. LtdINDUSTRY | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02268045 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | completed | Phase 3 | 272 | mAbxience Research S.L.INDUSTRY | 12 | Sep 26, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT00210353 | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma | completed | Phase 3 | 454 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 6 | Jun 6, 2019 | clinicaltrials |
| NCT03777085 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 3 | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2019 | clinicaltrials |
| NCT03952572 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 3 | 244 | Peking UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2021source: clinicaltrials